Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Pyridostigmine SR vs IR in Healthy Chinese Participants
NCT07154095Phase 1Completed
- Sponsor
- West China Second University Hospital
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pyridostigmine in myasthenia gravis (MG) (2 arms), sponsored by West China Second University Hospital. Primary endpoints: Time to Maximum Plasma Concentration at Day 5, Maximum Plasma Concentration at Day 5 and 1 more. Started Aug 2023; status: completed.
02
Drugs
pyridostigmine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07154095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154095.